Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 0.63 |
| ▸ | MLNR | O43193 | 1/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.63 |
| ▸ | CCKAR | P32238 | 1/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
| ▸ | GHSR | Q92847 | 1/20 | 0.63 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.63 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 5/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | CTSE | P14091 | 1/20 | 0.40 |
| ▸ | PGC | P20142 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887 | 0.97 | UGT1A1 (0.63) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL6169 | 0.95 | UGT1A1 (0.67) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL6164 | 0.94 | UGT1A1 (0.54) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL6550 | 0.94 | UGT1A1 (0.54) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL6837 | 0.93 | UGT1A1 (0.62) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL6749 | 0.92 | UGT1A1 (0.67) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL6229 | 0.91 | UGT1A1 (0.51) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL6221 | 0.90 | MLNR (0.52) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL7857673 | 0.90 | MLNR (0.52) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL5977 | 0.89 | UGT1A1 (0.66) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0900210-B1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | claimed |
| US-6166004-A | Combinations of HIV protease inhibitors with reverse transcriptase inhibitors | NOVARTIS FINANCE CORPORATION (US) | 2000-12-26 | — | — | US | claimed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | claimed |
| US-20130317040-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING HIV PROTEASE INHIBITORS | THE FEINSTEIN INSTITUTE OF MEDICAL RESEARCH (US) | 2013-11-28 | — | — | US | disclosed |
| EP-0900210-B1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| US-6300519-B1 | REACTING HYDRAZINE DERIVATIVE WITH EPOXIDE COMPOUND | NOVARTIS FINANCE CORPORATION | 2001-10-09 | — | — | US | disclosed |
| US-6166004-A | Combinations of HIV protease inhibitors with reverse transcriptase inhibitors | NOVARTIS FINANCE CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| US-6110946-A | AN ENZYME INHIBITORS OF RETROVIRAL ASPARTATE PROTEASE FOR THE TREATMENT OF AIDS | NOVARTIS FINANCE CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317040-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING HIV PROTEASE INHIBITORS | SSB, PREP, SERPINB1 | UGT1A1 1957/4885MLNR 2261/4885NR1I2 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.